What did Novo Nordisk CEO say about Wegovy price cuts?

Novo Nordisk CEO Mike Doustdar described the U.S. price reductions for Wegovy as 'painful' for the company's financial results but sees them as an investment in future access.

What was Novo Nordisk's outlook for 2026?

Novo Nordisk provided a worse-than-expected outlook for 2026, signaling a tough market ahead with pricing pressures.

Why are Wegovy price reductions considered an investment?

The CEO hopes that the price reductions for Wegovy will lead to increased accessibility of the medicines for more people in the future.

Home / Business and Economy / Novo Nordisk CEO: Wegovy Price Cuts Hurt, But Invest in Future

Novo Nordisk CEO: Wegovy Price Cuts Hurt, But Invest in Future

4 Feb

•

Summary

Wegovy price reductions in the U.S. are 'painful' for Novo Nordisk.
CEO hopes price cuts will increase future access to medicines.
Company gave a worse-than-expected outlook for 2026.

Novo Nordisk CEO: Wegovy Price Cuts Hurt, But Invest in Future

Novo Nordisk CEO Mike Doustdar acknowledged that recent price reductions for the obesity drug Wegovy in the United States are causing financial strain for the company. Despite the immediate impact, Doustdar views these adjustments as a strategic investment poised to enhance future accessibility of their medications.

This statement followed Novo Nordisk's Tuesday announcement of a considerably more challenging 2026 outlook than previously projected. The company also indicated a tough competitive landscape ahead, with escalating pressure on pricing within the weight-loss drug market.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.